急性リンパ芽球検査の世界市場見通し2023年-2029年

◆英語タイトル:Acute Lymphoblastic Testing Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書(MMG23FB2152)◆商品コード:MMG23FB2152
◆発行会社(リサーチ会社):Market Monitor Global
◆発行日:2023年2月
◆ページ数:66
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の急性リンパ芽球検査市場規模と予測を収録しています。・世界の急性リンパ芽球検査市場:売上、2018年-2023年、2024年-2029年
・世界の急性リンパ芽球検査市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の急性リンパ芽球検査市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「Bリンパ球検査」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

急性リンパ芽球検査のグローバル主要企業は、DrLal Path Labs、Bio-Rad Lab、Qiagen、Invivoscribe、Illumina、ArcherDx、Asuragen、Adaptive Biotechnologies、NeoGenomics Lab、Laboratory Corporation of America Holdings、ARUP Labなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、急性リンパ芽球検査のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の急性リンパ芽球検査市場:タイプ別、2018年-2023年、2024年-2029年
世界の急性リンパ芽球検査市場:タイプ別市場シェア、2022年
・Bリンパ球検査、Tリンパ球検査、その他

世界の急性リンパ芽球検査市場:用途別、2018年-2023年、2024年-2029年
世界の急性リンパ芽球検査市場:用途別市場シェア、2022年
・臨床検査室、病院、学術・研究機関、その他

世界の急性リンパ芽球検査市場:地域・国別、2018年-2023年、2024年-2029年
世界の急性リンパ芽球検査市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における急性リンパ芽球検査のグローバル売上、2018年-2023年
・主要企業における急性リンパ芽球検査のグローバル売上シェア、2022年
・主要企業における急性リンパ芽球検査のグローバル販売量、2018年-2023年
・主要企業における急性リンパ芽球検査のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
DrLal Path Labs、Bio-Rad Lab、Qiagen、Invivoscribe、Illumina、ArcherDx、Asuragen、Adaptive Biotechnologies、NeoGenomics Lab、Laboratory Corporation of America Holdings、ARUP Lab

*************************************************************

・調査・分析レポートの概要
急性リンパ芽球検査市場の定義
市場セグメント
世界の急性リンパ芽球検査市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の急性リンパ芽球検査市場規模
世界の急性リンパ芽球検査市場規模:2022年 VS 2029年
世界の急性リンパ芽球検査市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの急性リンパ芽球検査の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の急性リンパ芽球検査製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:Bリンパ球検査、Tリンパ球検査、その他
急性リンパ芽球検査のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:臨床検査室、病院、学術・研究機関、その他
急性リンパ芽球検査の用途別グローバル売上・予測

・地域別市場分析
地域別急性リンパ芽球検査市場規模 2022年と2029年
地域別急性リンパ芽球検査売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
DrLal Path Labs、Bio-Rad Lab、Qiagen、Invivoscribe、Illumina、ArcherDx、Asuragen、Adaptive Biotechnologies、NeoGenomics Lab、Laboratory Corporation of America Holdings、ARUP Lab
...

This report aims to provide a comprehensive presentation of the global market for Acute Lymphoblastic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Lymphoblastic Testing. This report contains market size and forecasts of Acute Lymphoblastic Testing in global, including the following market information:
Global Acute Lymphoblastic Testing Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Acute Lymphoblastic Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
B lymphocytes Testing Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Acute Lymphoblastic Testing include DrLal Path Labs, Bio-Rad Lab, Qiagen, Invivoscribe, Illumina, ArcherDx, Asuragen, Adaptive Biotechnologies and NeoGenomics Lab, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Lymphoblastic Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Acute Lymphoblastic Testing Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Acute Lymphoblastic Testing Market Segment Percentages, by Type, 2022 (%)
B lymphocytes Testing
T lymphocyte Testing
Others
Global Acute Lymphoblastic Testing Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Acute Lymphoblastic Testing Market Segment Percentages, by Application, 2022 (%)
Clinical Laboratories
Hospitals
Academic and Research Institutes
Others
Global Acute Lymphoblastic Testing Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Acute Lymphoblastic Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Lymphoblastic Testing revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Acute Lymphoblastic Testing revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
DrLal Path Labs
Bio-Rad Lab
Qiagen
Invivoscribe
Illumina
ArcherDx
Asuragen
Adaptive Biotechnologies
NeoGenomics Lab
Laboratory Corporation of America Holdings
ARUP Lab
Outline of Major Chapters:
Chapter 1: Introduces the definition of Acute Lymphoblastic Testing, market overview.
Chapter 2: Global Acute Lymphoblastic Testing market size in revenue.
Chapter 3: Detailed analysis of Acute Lymphoblastic Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Lymphoblastic Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Acute Lymphoblastic Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Acute Lymphoblastic Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Acute Lymphoblastic Testing Overall Market Size
2.1 Global Acute Lymphoblastic Testing Market Size: 2022 VS 2029
2.2 Global Acute Lymphoblastic Testing Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Acute Lymphoblastic Testing Players in Global Market
3.2 Top Global Acute Lymphoblastic Testing Companies Ranked by Revenue
3.3 Global Acute Lymphoblastic Testing Revenue by Companies
3.4 Top 3 and Top 5 Acute Lymphoblastic Testing Companies in Global Market, by Revenue in 2022
3.5 Global Companies Acute Lymphoblastic Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Acute Lymphoblastic Testing Players in Global Market
3.6.1 List of Global Tier 1 Acute Lymphoblastic Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 Acute Lymphoblastic Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Acute Lymphoblastic Testing Market Size Markets, 2022 & 2029
4.1.2 B lymphocytes Testing
4.1.3 T lymphocyte Testing
4.1.4 Others
4.2 By Type – Global Acute Lymphoblastic Testing Revenue & Forecasts
4.2.1 By Type – Global Acute Lymphoblastic Testing Revenue, 2018-2023
4.2.2 By Type – Global Acute Lymphoblastic Testing Revenue, 2024-2029
4.2.3 By Type – Global Acute Lymphoblastic Testing Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Acute Lymphoblastic Testing Market Size, 2022 & 2029
5.1.2 Clinical Laboratories
5.1.3 Hospitals
5.1.4 Academic and Research Institutes
5.1.5 Others
5.2 By Application – Global Acute Lymphoblastic Testing Revenue & Forecasts
5.2.1 By Application – Global Acute Lymphoblastic Testing Revenue, 2018-2023
5.2.2 By Application – Global Acute Lymphoblastic Testing Revenue, 2024-2029
5.2.3 By Application – Global Acute Lymphoblastic Testing Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Acute Lymphoblastic Testing Market Size, 2022 & 2029
6.2 By Region – Global Acute Lymphoblastic Testing Revenue & Forecasts
6.2.1 By Region – Global Acute Lymphoblastic Testing Revenue, 2018-2023
6.2.2 By Region – Global Acute Lymphoblastic Testing Revenue, 2024-2029
6.2.3 By Region – Global Acute Lymphoblastic Testing Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Acute Lymphoblastic Testing Revenue, 2018-2029
6.3.2 US Acute Lymphoblastic Testing Market Size, 2018-2029
6.3.3 Canada Acute Lymphoblastic Testing Market Size, 2018-2029
6.3.4 Mexico Acute Lymphoblastic Testing Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Acute Lymphoblastic Testing Revenue, 2018-2029
6.4.2 Germany Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.3 France Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.4 U.K. Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.5 Italy Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.6 Russia Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.7 Nordic Countries Acute Lymphoblastic Testing Market Size, 2018-2029
6.4.8 Benelux Acute Lymphoblastic Testing Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Acute Lymphoblastic Testing Revenue, 2018-2029
6.5.2 China Acute Lymphoblastic Testing Market Size, 2018-2029
6.5.3 Japan Acute Lymphoblastic Testing Market Size, 2018-2029
6.5.4 South Korea Acute Lymphoblastic Testing Market Size, 2018-2029
6.5.5 Southeast Asia Acute Lymphoblastic Testing Market Size, 2018-2029
6.5.6 India Acute Lymphoblastic Testing Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Acute Lymphoblastic Testing Revenue, 2018-2029
6.6.2 Brazil Acute Lymphoblastic Testing Market Size, 2018-2029
6.6.3 Argentina Acute Lymphoblastic Testing Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Acute Lymphoblastic Testing Revenue, 2018-2029
6.7.2 Turkey Acute Lymphoblastic Testing Market Size, 2018-2029
6.7.3 Israel Acute Lymphoblastic Testing Market Size, 2018-2029
6.7.4 Saudi Arabia Acute Lymphoblastic Testing Market Size, 2018-2029
6.7.5 UAE Acute Lymphoblastic Testing Market Size, 2018-2029
7 Acute Lymphoblastic Testing Companies Profiles
7.1 DrLal Path Labs
7.1.1 DrLal Path Labs Company Summary
7.1.2 DrLal Path Labs Business Overview
7.1.3 DrLal Path Labs Acute Lymphoblastic Testing Major Product Offerings
7.1.4 DrLal Path Labs Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.1.5 DrLal Path Labs Key News & Latest Developments
7.2 Bio-Rad Lab
7.2.1 Bio-Rad Lab Company Summary
7.2.2 Bio-Rad Lab Business Overview
7.2.3 Bio-Rad Lab Acute Lymphoblastic Testing Major Product Offerings
7.2.4 Bio-Rad Lab Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.2.5 Bio-Rad Lab Key News & Latest Developments
7.3 Qiagen
7.3.1 Qiagen Company Summary
7.3.2 Qiagen Business Overview
7.3.3 Qiagen Acute Lymphoblastic Testing Major Product Offerings
7.3.4 Qiagen Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.3.5 Qiagen Key News & Latest Developments
7.4 Invivoscribe
7.4.1 Invivoscribe Company Summary
7.4.2 Invivoscribe Business Overview
7.4.3 Invivoscribe Acute Lymphoblastic Testing Major Product Offerings
7.4.4 Invivoscribe Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.4.5 Invivoscribe Key News & Latest Developments
7.5 Illumina
7.5.1 Illumina Company Summary
7.5.2 Illumina Business Overview
7.5.3 Illumina Acute Lymphoblastic Testing Major Product Offerings
7.5.4 Illumina Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.5.5 Illumina Key News & Latest Developments
7.6 ArcherDx
7.6.1 ArcherDx Company Summary
7.6.2 ArcherDx Business Overview
7.6.3 ArcherDx Acute Lymphoblastic Testing Major Product Offerings
7.6.4 ArcherDx Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.6.5 ArcherDx Key News & Latest Developments
7.7 Asuragen
7.7.1 Asuragen Company Summary
7.7.2 Asuragen Business Overview
7.7.3 Asuragen Acute Lymphoblastic Testing Major Product Offerings
7.7.4 Asuragen Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.7.5 Asuragen Key News & Latest Developments
7.8 Adaptive Biotechnologies
7.8.1 Adaptive Biotechnologies Company Summary
7.8.2 Adaptive Biotechnologies Business Overview
7.8.3 Adaptive Biotechnologies Acute Lymphoblastic Testing Major Product Offerings
7.8.4 Adaptive Biotechnologies Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.8.5 Adaptive Biotechnologies Key News & Latest Developments
7.9 NeoGenomics Lab
7.9.1 NeoGenomics Lab Company Summary
7.9.2 NeoGenomics Lab Business Overview
7.9.3 NeoGenomics Lab Acute Lymphoblastic Testing Major Product Offerings
7.9.4 NeoGenomics Lab Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.9.5 NeoGenomics Lab Key News & Latest Developments
7.10 Laboratory Corporation of America Holdings
7.10.1 Laboratory Corporation of America Holdings Company Summary
7.10.2 Laboratory Corporation of America Holdings Business Overview
7.10.3 Laboratory Corporation of America Holdings Acute Lymphoblastic Testing Major Product Offerings
7.10.4 Laboratory Corporation of America Holdings Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.10.5 Laboratory Corporation of America Holdings Key News & Latest Developments
7.11 ARUP Lab
7.11.1 ARUP Lab Company Summary
7.11.2 ARUP Lab Business Overview
7.11.3 ARUP Lab Acute Lymphoblastic Testing Major Product Offerings
7.11.4 ARUP Lab Acute Lymphoblastic Testing Revenue in Global Market (2018-2023)
7.11.5 ARUP Lab Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 急性リンパ芽球検査の世界市場見通し2023年-2029年(Acute Lymphoblastic Testing Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。